Evolent Health, Inc. (NYSE:EVH) Director Acquires $25,517.55 in Stock

Evolent Health, Inc. (NYSE:EVH) Director Diane Holder bought 2,735 shares of the stock in a transaction on Thursday, March 6th. The shares were acquired at an average cost of $9.33 per share, with a total value of $25,517.55. Following the purchase, the director now owns 70,584 shares of the company’s stock, valued at approximately $658,548.72. This represents a 4.03 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Evolent Health Trading Up 0.6 %

NYSE:EVH traded up $0.05 on Monday, reaching $9.04. 643,570 shares of the stock traded hands, compared to its average volume of 2,054,103. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.58. Evolent Health, Inc. has a 1-year low of $8.35 and a 1-year high of $34.51. The company’s 50 day moving average is $10.37 and its 200-day moving average is $17.61. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of -11.14 and a beta of 1.49.

Evolent Health (NYSE:EVH) last posted its quarterly earnings data on Thursday, February 20th. The technology company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.38 by ($0.35). The firm had revenue of $646.54 million for the quarter, compared to analyst estimates of $650.92 million. Evolent Health had a positive return on equity of 5.73% and a negative net margin of 2.41%. Equities research analysts anticipate that Evolent Health, Inc. will post 0.08 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Covestor Ltd increased its holdings in Evolent Health by 138.1% in the third quarter. Covestor Ltd now owns 1,424 shares of the technology company’s stock worth $40,000 after purchasing an additional 826 shares in the last quarter. Summit Creek Advisors LLC boosted its holdings in shares of Evolent Health by 0.8% during the 4th quarter. Summit Creek Advisors LLC now owns 202,114 shares of the technology company’s stock worth $2,274,000 after buying an additional 1,636 shares in the last quarter. Pilgrim Partners Asia Pte Ltd acquired a new stake in shares of Evolent Health during the 4th quarter worth approximately $26,000. Parkside Financial Bank & Trust increased its stake in shares of Evolent Health by 90.7% in the 4th quarter. Parkside Financial Bank & Trust now owns 4,957 shares of the technology company’s stock valued at $56,000 after acquiring an additional 2,358 shares in the last quarter. Finally, Johnson Investment Counsel Inc. increased its stake in shares of Evolent Health by 28.0% in the 4th quarter. Johnson Investment Counsel Inc. now owns 11,607 shares of the technology company’s stock valued at $131,000 after acquiring an additional 2,542 shares in the last quarter.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Stephens decreased their target price on shares of Evolent Health from $16.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Tuesday, January 21st. Royal Bank of Canada reduced their price objective on Evolent Health from $20.00 to $17.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 14th. UBS Group lowered their target price on Evolent Health from $27.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, January 16th. JMP Securities reissued a “market outperform” rating and set a $12.00 price target on shares of Evolent Health in a research note on Friday, February 14th. Finally, Canaccord Genuity Group reduced their price target on Evolent Health from $23.00 to $16.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. One equities research analyst has rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $17.79.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.